Showing results (31-40 of 124) with videos related to
Sort By:
Pageof 13
Journal of Wound Care|June 6, 2019
Estimating the health-care costs of wound care in IrelandPaddy Gillespie, Laura Carter, Caroline McIntosh, et al.Allergy and Asthma Proceedings|September 2, 2020
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data baseHector Ortega, Beth Hahn, Michael Bogart, et al.Allergology International : Official Journal of the Japanese Society of Allergology|January 24, 2017
Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthmaTerufumi Shimoda, Hiroshi Odajima, Arisa Okamasa, et al.Antiviral Research|December 3, 2014
Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis CAnita Y M Howe, Jianmin Long, David Nickle, et al.Journal of Hazardous Materials|April 29, 2025
A framework to assess pharmaceutical accumulation in crops: from wastewater irrigation to consumptionJohn Nightingale, Stefan Trapp, Andrea Garduño-Jiménez, et al.Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|June 15, 2019
Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trialHector Ortega, Catherine Lemiere, Jean-Pierre Llanos, et al.Journal of Asthma and Allergy|February 27, 2020
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and CostsJean-Pierre Llanos, Hector Ortega, Michael Bogart, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2018
Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic AsthmaHector Ortega, Steven W Yancey, Oliver N Keene, et al.Current Medical Research and Opinion|August 28, 2009
Assessment of asthma control in primary careMatthew Mintz, Alicia W Gilsenan, Christine L Bui, et al.Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 30, 2019
A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthmaHector Ortega, Mary Fitzgerald, Kartik Raghupathi, et al.Pageof 13